Cite
MLA Citation
Nathan H. Fowler et al.. “Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma.” Journal of clinical oncology, vol. 39, no. 15, 2021, pp. 1609–1618. http://access.bl.uk/ark:/81055/vdc_100168590130.0x000010